Compare CVS Health Corp (CVS) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs 3M Company — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while 3M Company trades at $163.73 (market cap $83.61B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and 3M Company for 169 Days on average.
| CVS | MMM | |
|---|---|---|
Market Cap | $112.49B | $83.61B |
Volume | 8,467,392 | 3,188,723 |
Sector | Health | Industrials |
52-Week High | $110.60 | $183.79 |
52-Week Low | $70.08 | $141.10 |
Typical Hold Time | 83 Days | 169 Days |
Enterprise Value | $174.83B | $92.83B |
Dividend Yield | 3.02% | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
3M (MMM) trades at $163.57, showing minimal daily movement (-0.04%) amid a bearish technical outlook. The company demonstrates strong profitability with 11.9% net margins and impressive ROE of 82.77%, though revenue has declined from 2022 peaks. Recent Q2 2026 earnings beat expectations with 5.4% organic growth, supporting management's turnaround narrative. Analyst sentiment is evenly split between Buy and Hold ratings with a $191 consensus target representing 17% upside potential.
The stock presents a value opportunity with manageable litigation risks, but faces headwinds from weak consumer demand and high debt levels. Near-term catalysts include continued operational improvements and data-center expansion, while risks center on execution of margin targets and macroeconomic pressures on industrial markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
